Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands



Similar documents
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

What Does My Bone Marrow Do?

Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality

Mechanisms of Interferon-associated Bone Marrow Suppression with or without Ribavirin. K. Zhdanov

Anemia and chronic kidney disease

Prognostic impact of uric acid in patients with stable coronary artery disease

Rheumatoid arthritis: an overview. Christine Pham MD

Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D

06 Validation of risk prediction model

RR 0.88 (95% CI: ) P=0.051 (superiority) 3.75

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

Multimarker Approach to Risk Stratification Among Patients with Advanced Chronic Heart Failure

Rikshospitalet, University of Oslo

Peripheral Blood Stem Cell (PBSC) Collections: Why, What, When. Objectives. Sources of Stem Cells

Anemia and Erythropoietin in Cardiovascular Disease Lennaert Kleijn

DEPARTMENT OF IMMUNOLOGY Chair of Histology and Immunology Medical University of Gdańsk

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr

Controversies in the management of patients with PMF 0/1

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012

Laboratory Studies in the Diagnosis of Iron Deficiency, Latent Iron Deficiency and Iron Deficient Erythropoiesis

INSTEAD at 5-year follow-up shifts the expectations for endovascular treatment

Automated and Standardized Counting of CFU Assays of Human Hematopoietic Cells

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

How should we treat atrial fibrillation in heart failure

James F. Kravec, M.D., F.A.C.P

Hepatitis C. Laboratory Tests and Hepatitis C

Interpretation of Laboratory Values

AUTOMATION OF THE COLONY-FORMING CELL ASSAY FOR MEASURING HEMATOPOIETIC PROGENITORS IN CORD BLOOD

Drug Development Services

Iron Deficiency in Blood Donors

Journal of the American College of Cardiology Vol. 38, No. 2, by the American College of Cardiology ISSN /01/$20.

Effect of implanted device-based impedance monitoring with telemedicine alerts on mortality and morbidity in heart failure (OptiLink HF)

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS

Telemedicine in the Prevention and Monitoring of Heart Disease

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Does chronic lymphocytic leukemia increase the risk of osteoporosis?

Automated and Standardized Counting of CFU Assays for Cord Blood Banks

Development of Bone Metastases in Men With Prostate Cancer

Things You Don t Want to Miss in Multiple Myeloma

Platelet Review July Thomas S. Kickler M.D. Johns Hopkins University School of Medicine

Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, th Annual Great Lakes Cancer Nursing Conference Troy, MI

Proceeding of the ACVP/ASVCP Concurrent Annual Meetings

Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.

HA Territory-wide PCI Audit

INHERIT. The Lancet Diabetes & Endocrinology In press

How to evaluate vitamin and iron deficiency in practice?

RDW-- Interpreting the Full Blood Count

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:

Brain as a Target for Triiodothyronine

Stem Cell Transplantation In Patients with Fanconi Anemia

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Cord Blood Market Trends, circa 2014

Cloud Computing / Tele- Health in a Novel Integrated CHF Disease Management Program: The Israeli Experience

SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April Reference: NHSCB/A09/PS/b

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Inpatient Heart Failure Management: Risks & Benefits

Implementation of a high volume, complex clinical pathway for cardiothoracic surgery patients in the intensive care unit.

Dorset Cardiac Centre

Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University

Jennifer G. Collins, RN Children s Hospital of Chicago

Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013

Vitamin A Deficiency: Counting the Cost in Women s Lives

Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies

How do you decide on rate versus rhythm control?

GRANIX (tbo-filgrastim)

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.

Management of Atrial Fibrillation in Heart Failure

Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension

InDependent Diabetes Trust

Approach to Abnormal Liver Tests

survival, morality, & causes of death Chapter Nine introduction 152 mortality in high- & low-risk patients 154 predictors of mortality 156

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH

BioResearch. Hematopoietic and Immune Cell Products Essential Tools for Hematopoietic Research

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using

Updated Cardiac Resynchronization Therapy Guidelines

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working

FDA-approved label for epoetin alfa (Epogen, Procrit ) 2

on behalf of the AUGMENT-HF Investigators

ECG may be indicated for patients with cardiovascular risk factors


Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

Supplementary Online Content

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model

Infusion of allogeneic umbilical cord blood hematopoietic stem cells in patients with chemotherapy related myelosuppression

The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example

Dendritic Cells: A Basic Review *last updated May 2003

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

Basic Science in Medicine

Multivariate Logistic Regression

2012 Scientific Sessions of the ACC March 24, Emerson C Perin, MD, PhD

Diabetic Nephropathy

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Transcription:

Causes of Anemia in Patients with Heart Failure Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands

Background Anemia is common in patients with CHF Prevalence 15 55% Depends on: - Severity of CHF - Definition of anemia

Survival (%) Anemia in Heart Failure is associated with a higher mortality 100 80 Non-anemia 60 40 Anemia 20 0 10 20 30 40 50 60 Time (months) Van der Meer, 2004 JACC

Possible etiologies of anemia in HF Bone marrow - Insensitivity to EPO - Cytokines (TNF ) Malnutrition - Low iron - Vitamine B11,B12 Renal failure - EPO production Anemia Chronic blood loss - Use of Anticoagulation Medication - Use of ACE-inhibitors/ARB Hemodilution Van der Meer, Voors. Eur Heart J. 2004

Iron deficiency as major cause of anemia in 37 AHF patients

Possible etiologies of anemia in heart failure Bone marrow - Insensitivity to EPO - Cytokines (TNF ) Malnutrition - Low iron - Vitamine B11,B12 Renal failure - EPO production Anemia Chronic blood loss - Use of Anticoagulation Medication - Use of ACE-inhibitors/ARB Hemodilution Van der Meer, Voors. Eur Heart J. 2004

Eur Heart J 2007

Eur Heart J 2007

ECV is an independent predictor of anemia in patients with HF Eur Heart J 2007

Eur Heart J 2008

Hemodilution as a major cause of anemia in 100 CHF pts Eur Heart J 2008

Possible etiologies of anemia in heart failure Bone marrow - Insensitivity to EPO - Cytokines (TNF ) Malnutrition - Low iron - Vitamine B11,B12 Renal failure - EPO production Anemia Chronic blood loss - Use of Anticoagulation Medication - Use of ACE-inhibitors/ARB Hemodilution Van der Meer, Eur Heart J. 2004

Angiotensin II induces hematopoiesis Angiotensin stimulates proliferation of erythroid progenitors cells Losartan abolishes this stimulatory effect Mrug, JCI 1997

Interaction between RAS & hematopoiesis

Methods Population: 108 patients were included in this study 17 anemic HF patients (10 unexplained no hematinic abnormalities and no renal failure) 81 non-anemic HF patients 10 age-matched healthy controls All HF patients were in NYHA III All HF patients were using ACE-inhibitors Definition anemia (WHO): Males: Hemoglobin <8.1 mmol/l Females: Hemoglobin < 7.5 mmol/l vd Meer; Circulation 2005

Results Hematopoietic proliferation assay 120 p=0.003 p=0.48 BFU-E (%) 100 80 heart failure + anemia heart failure no-anemia healthy controls 60 0 vd Meer; Circulation 2005

Results 60 p=0.017 50 ACE-activity (U/L) 40 30 20 heart failure + anemia heart failure no-anemia 10 0 vd Meer; Circulation 2005

Results Ac-SDKP levels p=0.018 4 3 p=0.004 Ac - SDKP (nmol/l) 2 1 heart failure + anemia heart failure no-anemia healthy controls 0 vd Meer; Circulation 2005

Possible etiologies of anemia in heart failure Bone marrow - Insensitivity to EPO - Cytokines (TNF ) Malnutrition - Low iron - Vitamine B11,B12 Renal failure - EPO production Anemia Chronic blood loss - Use of Anticoagulation Medication - Use of ACE-inhibitors/ARB Hemodilution Van der Meer, Voors. Eur Heart J. 2004

Renal function is an independent predictor of anemia in patients with HF Eur Heart J 2007

Possible etiologies of anemia in heart failure Bone marrow - Insensitivity to EPO - Cytokines (TNF ) Malnutrition - Low iron - Vitamine B11,B12 Renal failure - EPO production Anemia Chronic blood loss - Use of Anticoagulation Medication - Use of ACE-inhibitors/ARB Hemodilution Van der Meer, Voors. Eur Heart J. 2004

Methods Patients 20 CHF patients (Age 67 years, LVEF 32%, 35% anemia) 20 age and gender matched controls (LVEF>50) Methods Bone marrow harvested from sternum during cardiac surgery Immunomagnetically isolated CD34 + hematopoietic progenitor cells in Erythroid lineage culture (incrementing doses of EPO) Myeloid culture (GM-CSF + IL-3) Mixed culture (SCF, EPO, IL-6, GM-CSF, IL-3) Correlation with the severity of CHF

160 Results (erythropoiesis) BFU-E / 10 4 CD34 + cells 140 120 100 80 60 40 20 P=0.015 CHF Control 0 0.02 0.1 0.2 1 2 10 EPO IU/ml

Myeloid culture Results (Myelopoiesis) CHF Control Mixed culture 200 Granulocyte 200 Granulocyte Erythroid Colonies / 10 4 CD34 + cells) 150 100 50 * Monocyte * Colonies / 10 4 CD34 + cells) 150 100 50 Monocyte * * * 0 CFU-G CFU-M 0 CFU-G CFU-M BFU-E * P<0.01 vs control

Results (CHF severity) 1000 R= -0.43 p=0.03 * 100 p=0.03 BFU-E / 10 4 CD34 + cells 100 BFU-E / 10 4 CD34 + cells 80 60 40 20 10 10 1 10 2 10 3 10 4 10 5 NTproBNP (pg/ml) 0 II III IV NYHA class Adusted R 2 0.5 adjusted for age, gender, surgical indication, cardiac medications, Hb and creatinine

Possible etiologies of anemia in heart failure Bone marrow - Insensitivity to EPO - Cytokines (TNF ) Malnutrition - Low iron - Vitamine B11,B12 Renal failure - EPO production Anemia Chronic blood loss - Use of Anticoagulation Medication - Use of ACE-inhibitors/ARB Hemodilution Van der Meer, Eur Heart J. 2004

Inflammation and anemia in HF 326 CHF patients; Hb, Ht, hscrp, IL-6, stnfr-1, EPO primary endpoint was all-cause mortality. FU was 18 months. Kleijn et al. Submitted

Inflammation and anemia in HF Logistic regression analysis; independent predictors of anaemia at baseline Variable Univariable Multivariable OR (95% CI) p-value OR (95% CI) p-value Age 1.31 (1.04-1.65) 0.022 Creatinine* 1.52 (1.20-1.92) <0.001 NT-proBNP* 1.53 (1.20-2.00) 0.001 stnfr-1* 1.79 (1.39-2.29) <0.001 1.62 (1.24-2.11) <0.001 hscrp* 1.46 (1.10-1.93) 0.008 1.58 (1.09-2.29) 0.016 Epo* 1.77 (1.38-2.27) <0.001 1.47 (1.11-1.93) 0.006 IL6 1.35 (1.10-1.65 0.004 Kleijn et al. Submitted

Inflammation and anemia in HF Kleijn et al. Submitted

Conclusions Lower hemoglobin levels often seen in HF patients and related to a poorer prognosis Multiple factors are involved, such as iron deficiency, hemodilution, ACEinhibitor, renal dysfunction, bone marrow dysfunction, and inflammation Anemia sign of poor clinical status or causative for poor outcome?